

Resource Summary Report

Generated by RRID on Aug 4, 2026

Dialog

RRID:SCR_008482

Type: Tool

Proper Citation

Dialog (RRID:SCR_008482)

Resource Information

URL: <http://www.dialog.com>

Proper Citation: Dialog (RRID:SCR_008482)

Description: Dialog provides critical information from the world's most authoritative publishers, combined with the tools to search every bit of it with speed and precision. With direct operations in 27 countries, Dialog products and services are a combination of highly accurate online research tools offering access to unique and relevant databases designed to meet the specific needs of a wide range of users. Information professionals and end-users at business, professional, scientific, academic and government organizations in more than 100 countries prize Dialog services to meet their searching needs. As part of the Deep Web, which is estimated to be 500 times larger than the content accessible via Web search engines, Dialog products offer unparalleled depth and breadth of content coupled with the ability to search with precision and speed. Our collection of over 900 databases handles more than 700,000 searches and delivers over 17 million document page views per month. Searchable content on Dialog services includes articles and reports from thousands of real-time news feeds, newspapers, broadcast transcripts and trade publications, plus market research reports and analyst notes providing support for financial decision-making, as well as in-depth repositories of scientific and technical data, patents, trademarks and other intellectual property data. Additional content areas include government regulations, social sciences, food and agriculture, reference, energy and environment, chemicals, pharmaceuticals and medicine.

Abbreviations: Dialog

Resource Type: topical portal, data or information resource, database, portal

Keywords: FASEB list

Resource Name: Dialog

Resource ID: SCR_008482

Alternate IDs: nif-0000-30451

Record Creation Time: 20220129T080247+0000

Record Last Update: 20260804T043404+0000

Ratings and Alerts

No rating or validation information has been found for Dialog.

No alerts have been found for Dialog.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 48 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Malik AM, et al. (2025) Helping people with psychosis with a low-cost intervention DIALOG+: protocol for the economic evaluation in a randomised control trial in India and Pakistan. *BMJ open*, 15(1), e080737.

Clausen D, et al. (2025) Wearable continuous diffusion-based skin gas analysis. *Nature communications*, 16(1), 4343.

Selak N, et al. (2025) Patients' and clinicians' experiences of DIALOG+ in primary health care in Bosnia and Herzegovina: a qualitative interview study using thematic analysis. *BMC primary care*, 26(1), 194.

Zhang X, et al. (2024) The serum levels of gasdermin D in uremic patients and its relationship with the prognosis: a prospective observational cohort study. *Renal failure*, 46(1), 2312534.

Alinaitwe R, et al. (2024) Acceptability of a resource-oriented approach (DIALOG+) among patients with chronic physical illnesses in primary health care-Uganda, a qualitative study. *BMC primary care*, 25(1), 429.

Tomar M, et al. (2024) Towards knowledge-infused automated disease diagnosis assistant. *Scientific reports*, 14(1), 13442.

Killaspy H, et al. (2024) Assessing the clinical and cost-effectiveness of inpatient mental health rehabilitation services provided by the NHS and independent sector (ACER): protocol. *BMC psychiatry*, 24(1), 104.

Gómez-Restrepo C, et al. (2023) Effectiveness of a Patient-Centered Assessment With a Solution-Focused Approach (DIALOG-A) in the Routine Care of Colombian Adolescents

With Depression and Anxiety: Protocol for a Multicenter Cluster Randomized Controlled Trial. JMIR research protocols, 12, e43401.

Hijiya N, et al. (2023) The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study. Blood advances, 7(23), 7279.

Correll CU, et al. (2023) Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis. The international journal of neuropsychopharmacology, 26(7), 451.

Bird VJ, et al. (2023) Assessing the effectiveness and cost-effectiveness of a solution-focused resource-orientated approach (DIALOG+) to improving the quality of life for people with psychosis in India and Pakistan-a cluster RCT. Trials, 24(1), 59.

Mehta H, et al. (2022) Outcomes of Over 40,000 Eyes Treated for Diabetic Macula Edema in Routine Clinical Practice: A Systematic Review and Meta-analysis. Advances in therapy, 39(12), 5376.

Jovanovi? N, et al. (2022) Improving treatment of patients with psychosis in low-and-middle-income countries in Southeast Europe: Results from a hybrid effectiveness-implementation, pragmatic, cluster-randomized clinical trial (IMPULSE). European psychiatry : the journal of the Association of European Psychiatrists, 65(1), e50.

Walczak M, et al. (2021) A preliminary metabolites identification of a novel compound with α -adrenolytic activity. Pharmacological reports : PR, 73(5), 1373.

Jones CI, et al. (2021) Statistical analysis plan for the Early Youth Engagement in first episode psychosis (EYE-2) study: a pragmatic cluster randomised controlled trial of implementation, effectiveness and cost-effectiveness of a team-based motivational engagement intervention to improve engagement. Trials, 22(1), 732.

Kodama S, et al. (2021) Ability of Current Machine Learning Algorithms to Predict and Detect Hypoglycemia in Patients With Diabetes Mellitus: Meta-analysis. JMIR diabetes, 6(1), e22458.

Greenwood K, et al. (2021) The Early Youth Engagement in first episode psychosis (EYE-2) study: pragmatic cluster randomised controlled trial of implementation, effectiveness and cost-effectiveness of a team-based motivational engagement intervention to improve engagement. Trials, 22(1), 272.

Garcia JS, et al. (2021) A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leukemia research, 104, 106555.

DeSesso JM, et al. (2021) Systematic assessment of quaternary ammonium compounds for the potential to elicit developmental and reproductive effects. Birth defects research, 113(20), 1484.

Stuart T, et al. (2021) Biosymbiotic, personalized, and digitally manufactured wireless devices for indefinite collection of high-fidelity biosignals. Science advances, 7(41), eabj3269.